Rongrong Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rongrong Zhou has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Gang Xiao
Department of Radiation Oncology, Xiangya Hospital, Central South University, Changsha, China
16 shared publicationsLiu Chen
Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China
14 shared publicationsXianjing Chu
The department of oncology, Xiangya Hospital, Central South University, Changsha, China
14 shared publicationsLishui Niu
The department of oncology, Xiangya Hospital, Central South University, Changsha, China
12 shared publicationsGuilong Tanzhu
The department of oncology, Xiangya Hospital, Central South University, Changsha, China
11 shared publicationsJiaoyang Ning
Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China
9 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1) , 384
Multi-cell death gene signature predicts lung adenocarcinoma prognosis and reveals FURIN regulates ferroptosis via NRF2-xCT-GPX4 axis
- 5 October 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1) , 384
Open AccessMulti-cell death gene signature predicts lung adenocarcinoma prognosis and reveals FURIN regulates ferroptosis via NRF2-xCT-GPX4 axis
- Open Access
- 6 July 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Radiogenomic modeling of EGFR mutation status in brain metastases from lung adenocarcinoma: a multicenter study with biological interpretability
Accurate prediction of epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma (LUAD) with brain metastases (BMs) is crucial for guiding targeted therapy. However, noninvasive and biologically interpretable tools remain limited. In this multicenter radiogenomic study, we analyzed a total of 1303 BMs from 421 LUAD patients across three institutions. 3435 radiomic features were extracted from T1, T2, and contrast-enhanced T1 sequences. A four-task classification framework was developed to predict EGFR mutation status (EGFR+, 19Del, L858R, or sensitizing mutation) using an adaptive LightGBM-based modeling pipeline. The models achieved excellent performance in the internal cohort (AUCs up to 0.95) and were further validated in 94 lesions with pathologically confirmed EGFR status, reaching an accuracy of 83.0%, sensitivity of 84.7%, and specificity of 80.0%. SHAP and LIME analyses revealed that shape-based radiomic features, particularly original_shape_sphericity, were the most important predictors of EGFR mutational subtypes. Then, we conducted transcriptomic analysis on 38 matched surgical specimens. Radiogenomic correlation revealed that sphericity negatively correlated with RNF125 and SLC37A2. Downstream enrichment analysis identified EGFR-associated features linked to DNA replication, sister chromatid segregation, and ERBB signaling. The study demonstrates that radiogenomic modeling, grounded in interpretable biology, holds promise as a non-invasive, clinical strategy for precision stratification of LUAD BMs.
- 6 July 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Open AccessRadiogenomic modeling of EGFR mutation status in brain metastases from lung adenocarcinoma: a multicenter study with biological interpretability
Accurate prediction of epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma (LUAD) with brain metastases (BMs) is crucial for guiding targeted therapy. However, noninvasive and biologically interpretable tools remain limited. In this multicenter radiogenomic study, we analyzed a total of 1303 BMs from 421 LUAD patients across three institutions. 3435 radiomic features were extracted from T1, T2, and contrast-enhanced T1 sequences. A four-task classification framework was developed to predict EGFR mutation status (EGFR+, 19Del, L858R, or sensitizing mutation) using an adaptive LightGBM-based modeling pipeline. The models achieved excellent performance in the internal cohort (AUCs up to 0.95) and were further validated in 94 lesions with pathologically confirmed EGFR status, reaching an accuracy of 83.0%, sensitivity of 84.7%, and specificity of 80.0%. SHAP and LIME analyses revealed that shape-based radiomic features, particularly original_shape_sphericity, were the most important predictors of EGFR mutational subtypes. Then, we conducted transcriptomic analysis on 38 matched surgical specimens. Radiogenomic correlation revealed that sphericity negatively correlated with RNF125 and SLC37A2. Downstream enrichment analysis identified EGFR-associated features linked to DNA replication, sister chromatid segregation, and ERBB signaling. The study demonstrates that radiogenomic modeling, grounded in interpretable biology, holds promise as a non-invasive, clinical strategy for precision stratification of LUAD BMs.
- Open Access
- 20 June 2026
- Published by Elsevier in Military Medical Research
- Vol. 13 (1)
Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances
- 20 June 2026
- Published by Elsevier in Military Medical Research
- Vol. 13 (1)
Open AccessCrosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances
- Open Access
- 31 May 2026
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 31 (1)
Lactate-activated astrocytes promote NSCLC brain metastasis through extracellular vesicle-mediated miR-8085/TRIM67/ELK1 signaling axis
Brain metastasis represents an advanced complication in non-small cell lung cancer (NSCLC), characterized by therapeutic resistance and dismal survival outcomes. Although astrocytes are known to influence tumor progression within the brain microenvironment, their prognostic significance and mechanistic contributions to NSCLC brain metastasis (NSCLC-BM) remain largely unresolved. In this study, we analyze brain metastatic tumors from 66 patients with NSCLC and demonstrate that high infiltration of astrocytes is significantly associated with reduced overall survival. Functional assays reveal that astrocytes enhance the stemness of metastatic tumor cells, a phenotype that is significantly attenuated by silencing astrocytic monocarboxylate transporter 1 (MCT1), thereby blocking lactate uptake. Mechanistically, lactate reprograms astrocytes to release extracellular vesicles enriched in miR-8085, which downregulates the E3 ubiquitin ligase TRIM67 in tumor cells. This suppression stabilizes the transcription factor ELK1 through inhibition of ubiquitin-mediated degradation, promoting stemness maintenance and tumorigenic capacity. Clinically, low TRIM67 and high ELK1 expression correlate with poorer survival in patients with NSCLC-BM. Together, our findings uncover a novel lactate-induced miR-8085/TRIM67/ELK1 signaling cascade that drives brain metastasis progression and highlight potential prognostic biomarkers and therapeutic targets for patients with NSCLC involving the brain.
- 31 May 2026
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 31 (1)
Open AccessLactate-activated astrocytes promote NSCLC brain metastasis through extracellular vesicle-mediated miR-8085/TRIM67/ELK1 signaling axis
Brain metastasis represents an advanced complication in non-small cell lung cancer (NSCLC), characterized by therapeutic resistance and dismal survival outcomes. Although astrocytes are known to influence tumor progression within the brain microenvironment, their prognostic significance and mechanistic contributions to NSCLC brain metastasis (NSCLC-BM) remain largely unresolved. In this study, we analyze brain metastatic tumors from 66 patients with NSCLC and demonstrate that high infiltration of astrocytes is significantly associated with reduced overall survival. Functional assays reveal that astrocytes enhance the stemness of metastatic tumor cells, a phenotype that is significantly attenuated by silencing astrocytic monocarboxylate transporter 1 (MCT1), thereby blocking lactate uptake. Mechanistically, lactate reprograms astrocytes to release extracellular vesicles enriched in miR-8085, which downregulates the E3 ubiquitin ligase TRIM67 in tumor cells. This suppression stabilizes the transcription factor ELK1 through inhibition of ubiquitin-mediated degradation, promoting stemness maintenance and tumorigenic capacity. Clinically, low TRIM67 and high ELK1 expression correlate with poorer survival in patients with NSCLC-BM. Together, our findings uncover a novel lactate-induced miR-8085/TRIM67/ELK1 signaling cascade that drives brain metastasis progression and highlight potential prognostic biomarkers and therapeutic targets for patients with NSCLC involving the brain.
- Open Access
- 30 April 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Integrative multi-omics profiling reveals distinct evolutionary and immunogenic features of brain oligometastasis in lung adenocarcinoma
Emerging evidence has demonstrated that lung cancer patients with brain oligometastases (oligo-BMs) could benefit from local radical therapies. Despite rap
- 30 April 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Open AccessIntegrative multi-omics profiling reveals distinct evolutionary and immunogenic features of brain oligometastasis in lung adenocarcinoma
Emerging evidence has demonstrated that lung cancer patients with brain oligometastases (oligo-BMs) could benefit from local radical therapies. Despite rap
- 1 January 2026
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 38 (4) , 606-623
Molecular subtyping of brain metastasis-related genes in lung adenocarcinoma via ScRNA-seq and bulk RNA-seq integration: A focus on TPX2
- 1 January 2026
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 38 (4) , 606-623
Molecular subtyping of brain metastasis-related genes in lung adenocarcinoma via ScRNA-seq and bulk RNA-seq integration: A focus on TPX2
- Open Access
- 27 July 2025
- Published by Elsevier in Brain Stimulation
- Vol. 18 (5) , 1426-1440
Tumor treating fields combined with ionizing radiation inhibit the malignant phenotype of lung cancer brain metastasis cells by suppressing DNA damage repair pathways
- 27 July 2025
- Published by Elsevier in Brain Stimulation
- Vol. 18 (5) , 1426-1440
Open AccessTumor treating fields combined with ionizing radiation inhibit the malignant phenotype of lung cancer brain metastasis cells by suppressing DNA damage repair pathways
- Top Cited PapersOpen Access
- 11 June 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-43
Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy
Radiotherapy (RT) remains a cornerstone treatment for over 50% of cancer patients, primarily via ionizing radiation-induced DNA damage to exert therapeutic effects. Notably, emerging studies have revealed its additional capacity to activate systemic anti-tumor immune responses through inducing immunogenic cell death (ICD) and activating the cGAS-STING pathway, further expanding its therapeutic potential. However, its efficacy is often limited by immunosuppressive tumor microenvironment (TME). Additionally, while RT can activate the cGAS-STING pathway, this activation remains transient and suboptimal, failing to sustain robust anti-tumor immunity. Therefore, combining RT with STING agonists may benefit traditional therapy by amplifing tumor immunogenicity and counteracting immune evasion. Despite promising results, challenges such as off-target toxicity, poor cell membrane permeability and poor bioavailability, remain obstacles to clinical translation of conventional STING agonists. Nanomedicine offers a promising approach by enabling targeted delivery of STING agonists and amplifying RT-induced DNA damage through nanoscale radiosensitizers. In this review, we provide a detailed discussion of the immune-stimulatory and immune-suppressive effects of RT, as well as the mechanisms and biological effects of selectively activating the cGAS-STING pathway in key TME components. On this basis, we further explore recent advancements in nano-STING agonists-mediated anti-tumor immunity in synergy with RT. This combinatorial approach achieves dual radiosensitization and immunostimulation, ultimately driving immune memory formation and TME reprogramming. Finally, the application prospects and challenges of nano-STING agonists-based immunotherapy are also discussed from the perspective of clinical translation.
- 11 June 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-43
Top Cited PapersOpen AccessEnhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy
Radiotherapy (RT) remains a cornerstone treatment for over 50% of cancer patients, primarily via ionizing radiation-induced DNA damage to exert therapeutic effects. Notably, emerging studies have revealed its additional capacity to activate systemic anti-tumor immune responses through inducing immunogenic cell death (ICD) and activating the cGAS-STING pathway, further expanding its therapeutic potential. However, its efficacy is often limited by immunosuppressive tumor microenvironment (TME). Additionally, while RT can activate the cGAS-STING pathway, this activation remains transient and suboptimal, failing to sustain robust anti-tumor immunity. Therefore, combining RT with STING agonists may benefit traditional therapy by amplifing tumor immunogenicity and counteracting immune evasion. Despite promising results, challenges such as off-target toxicity, poor cell membrane permeability and poor bioavailability, remain obstacles to clinical translation of conventional STING agonists. Nanomedicine offers a promising approach by enabling targeted delivery of STING agonists and amplifying RT-induced DNA damage through nanoscale radiosensitizers. In this review, we provide a detailed discussion of the immune-stimulatory and immune-suppressive effects of RT, as well as the mechanisms and biological effects of selectively activating the cGAS-STING pathway in key TME components. On this basis, we further explore recent advancements in nano-STING agonists-mediated anti-tumor immunity in synergy with RT. This combinatorial approach achieves dual radiosensitization and immunostimulation, ultimately driving immune memory formation and TME reprogramming. Finally, the application prospects and challenges of nano-STING agonists-based immunotherapy are also discussed from the perspective of clinical translation.
- 6 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1749-1750
Response to Zhang, Wang, Li, et al.
- 6 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1749-1750
Response to Zhang, Wang, Li, et al.
- Open Access
- 27 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer
This multi-center retrospective study aimed to evaluate the safety and efficacy of first-line immunotherapy in non-small-cell lung cancer (NSCLC) patients with brain metastases (BM). The study included 138 patients treated with immune checkpoint inhibitors (ICIs), either alone or in combination with brain radiotherapy (BRT), from 2020 to October 2023. Intracranial overall response rate (iORR), overall response rate (ORR), progression-free survival (PFS), intracranial progression-free survival (iPFS), overall survival (OS) and treatment-related toxicities were evaluated. Although patients receiving ICIs plus BRT showed a trend toward longer OS compared with ICI alone, the difference was not statistically significant (P = 0.201). Among 82 patients with available data, the iORR was 49.1% (35–63) in the ICIs alone group, and 75.9% (56–90) in the ICIs + BRT group. Notably, in patients requiring corticosteroids or mannitol, combination therapy was associated with a better prognosis (P = 0.05). We found that the iORR of patients treated with ICIs + BRT was improved and did not increase the incidence of serious adverse events (SAEs). Besides, the combination of ICIs and BRT improved the survival rate of subgroups of patients using corticosteroids.
- 27 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessA retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer
This multi-center retrospective study aimed to evaluate the safety and efficacy of first-line immunotherapy in non-small-cell lung cancer (NSCLC) patients with brain metastases (BM). The study included 138 patients treated with immune checkpoint inhibitors (ICIs), either alone or in combination with brain radiotherapy (BRT), from 2020 to October 2023. Intracranial overall response rate (iORR), overall response rate (ORR), progression-free survival (PFS), intracranial progression-free survival (iPFS), overall survival (OS) and treatment-related toxicities were evaluated. Although patients receiving ICIs plus BRT showed a trend toward longer OS compared with ICI alone, the difference was not statistically significant (P = 0.201). Among 82 patients with available data, the iORR was 49.1% (35–63) in the ICIs alone group, and 75.9% (56–90) in the ICIs + BRT group. Notably, in patients requiring corticosteroids or mannitol, combination therapy was associated with a better prognosis (P = 0.05). We found that the iORR of patients treated with ICIs + BRT was improved and did not increase the incidence of serious adverse events (SAEs). Besides, the combination of ICIs and BRT improved the survival rate of subgroups of patients using corticosteroids.